Navigation Links
Trubion Announces Acceptance of Three Presentations on Its TRU-016 Product Candidate at the 2009 ASCO Annual Meeting
Date:5/14/2009

ells and platelets.

Eight of the 10 patients had high-risk genomic features and no dose-limiting toxicities or serious adverse events had occurred. Mild (grade 1-2) infusion toxicity was observed in three patients. Beginning with the 0.3 mg/kg dose, all eight patients demonstrated evidence of biological activity including high-risk patients. Two patients had partial clearing of leukemia cutis, and the other six had 27% to 94% reduction in peripheral lymphocyte count. One patient had an increase in hemoglobin of 40% and a reduction in lymph nodes of 36%. Two patients had a significant increase in platelet count.

TRU-016 is a humanized SMIP protein therapeutic that targets the CD37 antigen and has shown potent anti-tumor activity in pre-clinical studies. Trubion initiated a Phase 1/2 clinical trial of TRU-016 in March 2008. The open-label clinical trial has two components: a Phase 1 dose escalation study designed to evaluate the safety, tolerability and pharmacokinetics of TRU-016, and a Phase 2 expansion cohort designed to further evaluate safety and estimate clinical activity of TRU-016 in patients with previously treated CLL or small lymphocytic lymphoma (SLL).

Abstract 8571 (May 30, 2009): Evaluation of the Effect of TRU-016 in Combination With Other Therapeutic Drugs in Models of Non-Hodgkin's Lymphoma

In addition, Trubion will also present at the 2009 ASCO Annual Meeting preclinical data evaluating TRU-016 interactions with the established therapeutics rituximab, doxorubicin, rapamycin, and bendamustine. Drugs were tested alone or in combination with TRU-016 for anti-proliferative effects on cell lines in vitro and on tumors in vivo.

Combination index analyses revealed that TRU-016 is synergistic with rituximab, bendamustine, or rapamycin and additive with doxorubicin in killing NHL cells in vitro. In vivo results show that treatment with the combination of TRU-016
'/>"/>

SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Trubion Announces Dates for First-Quarter 2009 Earnings Conference Call
2. Trubion Presents Preclinical Data on Its SCORPION(TM) Multispecific Therapeutics at the 2009 American Association of Cancer Research Annual Meeting
3. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
4. Trubion Pharmaceuticals Inc. Announces Work-Force Reductions and Restructuring
5. Trubion Announces Presentations at Upcoming Investor Conferences
6. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results
7. Trubion Announces Presentations at Upcoming Investor Conferences
8. Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
9. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
10. Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global Healthcare Unplugged Conference in New York
11. Trubion Pharmaceuticals to Present at the 7th Annual Needham & Company Biotechnology & Medical Technology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... , July 3, 2015 ... 22. september 2015 på  http://www.openinnovationinscience.at om ... der finder sted i Wien ... undersøgelse af internationale forskere og videnskabsmænd foretaget ... to største udfordringer for sundhedsvidenskaben manglen på ...
(Date:7/2/2015)... Md. , July 2, 2015  Spherix Incorporated ... to the fostering and monetization of intellectual property, today ... of Spherix Incorporated v. Verizon Services Corp. et ... District Court for the Eastern District of ... on July 1, 2015 interpreting certain key claims in ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... of surgical instruments in Orthopedics, announced today the acquisition of Turner Medical, ... largest provider of surgical instruments to the Spine Industry. The acquisition of Turner ...
(Date:7/1/2015)...   Decision Resources Group finds that ... are its oral administration, alternative mechanism of action, ... rheumatologists. Otezla was the first oral therapy specifically ... psoriatic arthritis in the United States ... conventional oral treatments including disease-modifying antirheumatic drugs (DMARDs), ...
Breaking Biology Technology:Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 2Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 3Spherix Issues A Litigation Update 2Spherix Issues A Litigation Update 3In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3
... , , SUNRISE, Fla., July 28 ... delivering intelligent devices and biologics that help monitor, diagnose and treat ... cleared a phase I clinical trial for MyoCell SDF-1 (Stromal Derived ... trial will enroll 15 patients in a multicenter, randomized, dose escalation ...
... , , , ... CYNO ), a leading developer and manufacturer of a broad array of ... June 30, 2009. , , Second Quarter 2009 Financial ... June 30, 2009 were $20.8 million, compared with $39.2 million in the same ...
... BIRMINGHAM, Ala., July 28 BioCryst Pharmaceuticals (Nasdaq: ... financial results will be released on Thursday, July 30, 2009. ... at 11:00 a.m. Eastern Time to discuss the financial results ... call will be led by Jon P. Stonehouse, President and ...
Cached Biology Technology:United States FDA Clears the REGEN Trial to Test Bioheart's Combination Gene and Stem Cell Therapy in Heart Failure Patients 2United States FDA Clears the REGEN Trial to Test Bioheart's Combination Gene and Stem Cell Therapy in Heart Failure Patients 3United States FDA Clears the REGEN Trial to Test Bioheart's Combination Gene and Stem Cell Therapy in Heart Failure Patients 4Cynosure Reports Second Quarter 2009 Financial Results 2Cynosure Reports Second Quarter 2009 Financial Results 3Cynosure Reports Second Quarter 2009 Financial Results 4Cynosure Reports Second Quarter 2009 Financial Results 5Cynosure Reports Second Quarter 2009 Financial Results 6Cynosure Reports Second Quarter 2009 Financial Results 7Cynosure Reports Second Quarter 2009 Financial Results 8Cynosure Reports Second Quarter 2009 Financial Results 9Cynosure Reports Second Quarter 2009 Financial Results 10Cynosure Reports Second Quarter 2009 Financial Results 11Cynosure Reports Second Quarter 2009 Financial Results 12Cynosure Reports Second Quarter 2009 Financial Results 13BioCryst Pharmaceuticals to Announce Second Quarter 2009 Financial Results on July 30, 2009 2
(Date:6/23/2015)... 23, 2015   MedNet Solutions , an ... entire spectrum of clinical research, is pleased to ... , the company,s intuitive, flexible and affordable cloud-based ... 2015 Stevie® Award by the American Business ... Website category.  The American Business Awards are considered ...
(Date:6/18/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") ... market announces that its Wocket® smart wallet will be the ... scheduled to air on WABC Radio (am770) in ... The broadcast air- time for the extensive one ... Inc.,s CEO Gino Pereira will be discussing its ...
(Date:6/16/2015)... 2015 /CNW Telbec/ - handyem Inc. and FlowMetric ... incorporation of handyem,s HPC-150 portable flow cytometer within ... This unprecedented model of mobile laboratory platform is ... Pennsylvania Convention Center, ... to 18 th 2015.  By virtue ...
Breaking Biology News(10 mins):MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3
... of great whales ever recorded? To answer that ... the Wildlife Conservation Society have joined experts from other ... Commission on the Patagonian coast of Argentina to try ... issue is the long-term conservation of the southern right ...
... "Four and 20 black birds baked in a pie" but ... analysis, means scientists now know there is one more species of ... thought. And if Dr. Gary Voelker has his way, he,ll soon ... deforestation now occurring across its native habitat. The bird ...
... resistance to sea lice treatments such as the pyrethroids ... Pyrethroid use still increased from 2008 to 2009, although ... are being used again due to resistance problems, e.g. ... been used since 1997, was also used again in ...
Cached Biology News:Experts gather to solve mystery of largest recorded die-off of great whales 2Experts gather to solve mystery of largest recorded die-off of great whales 3African bird discovery proves there is something new under the sun 2
iEMS Thermal Microplate Holder...
...
Improve inventory management with stainless steel red cell canisters; ensure product safety with CO2 or LN2 backup systems. A complete solution for your blood banking needs....
... oligonucleotides: PTOs are internucleotide modifications, ... backbone is replaced by a sulphur atom. ... degradation. PTOs are available as ... Oligonucleotides with thio-caps ...
Biology Products: